free PDF file: The Use of Partial Fatty Acid Oxidation Inhibitors for Metabolic Therapy of Angina Pectoris and Heart Failure

Functional Genomics of the Pressure Overloaded Cardiomyocyte. Is Heart Failure a Target for Etomoxir? 

Acute Heart Failure Basic Pathomechanism and New Drug Targets.

Deficiency of EPA and DHA in dilative heart failure - a rational teatment target for omega-3 fatty acids:
Rupp H, Rupp TP, Alter P, Maisch B. Can J Physiol Pharmacol. 2012;90:55-73 Open Access
Mechanisms involved in the differential reduction of omega-3 and omega-6 highly unsaturated fatty acids by structural heart disease resulting in "HUFA deficiency".

Determination of omega-3 fatty acids in the blood and risk stratification by the EPA+DHA level
Rupp H, Rupp TP, Wagner D, Alter P, Maisch B. Microdetermination of fatty acids by gas chromatography and cardiovascular risk stratification by the "EPA+DHA level". Herz 2006;31Suppl 3:30-49 (available as PDF)

Risk stratification by the EPA+DHA level and the EPA/arachidonic acid (EPA/AA) ratio
Rupp H, Wagner D, Rupp T, Schulte L, Maisch B. Risk stratification by the "EPA+DHA Level" and the "EPA/AA Ratio". Focus on anti-inflammatory and antiarrythmogenic effects of long-chain omega-3 fatty acids. Herz 2004; 29:673-685 (available as PDF)

Carditis Net


November 12, 2013